drugset / Trial / NCT02250573

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

NCT02250573 ↗

Phase 3 Completed Bio Products Laboratory
Treatment

Summary

The main objectives of this study were to investigate the safety and efficacy of Replenine®-VF administered in appropriate dosage by bolus infusion to prevent bleeding and achieve haemostasis in subjects with haemophilia B undergoing surgery.

Timeline

Start
2005-12
Primary completion
2006-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Replenine®-VF Protein / enzyme biologic — Other

Indications